Management options for metastatic melanoma in the era of novel therapies: A primer for the practicing dermatologist: Part I: Management of stage III disease

Journal of the American Academy of Dermatology

Volumn 68, Issue 1, 2013, Pages 1.e1-1.e9

  Fox, Matthew C ^a   Lao, Christopher D ^a   Schwartz, Jennifer L ^a   Frohm, Marcus L ^a   Bichakjian, Christopher K ^a   Johnson, Timothy M ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

adjuvant treatment; in transit metastases; interferon; melanoma

Indexed keywords

ANTINEOPLASTIC AGENT; CANCER VACCINE; CISPLATIN; DACARBAZINE; IMIQUIMOD; IPILIMUMAB; PLACEBO; RECOMBINANT ALPHA2B INTERFERON; VEMURAFENIB; VINBLASTINE;

ANOREXIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CHILL; DEPRESSION; DISEASE SEVERITY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG MEGADOSE; EXCISION; FATIGUE; FEVER; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; HUMAN; IN-TRANSIT METASTASIS; LIMB PERFUSION; LIVER DYSFUNCTION; LYMPH NODE DISSECTION; MALAISE; METASTATIC MELANOMA; MOOD CHANGE; NAUSEA AND VOMITING; OVERALL SURVIVAL; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; SENTINEL LYMPH NODE BIOPSY; SIDE EFFECT;

EID: 84870932997     PISSN: 01909622     EISSN: 10976787     Source Type: Journal    
DOI: 10.1016/j.jaad.2012.09.040     Document Type: Review

References (48)

1. American Cancer Society web site. Melanoma skin cancer overview. Available from http://www.cancer.org/cancer/skincancer-melanoma/overviewguide/ melanoma-skin-cancer-overview-key-statistics. Accessed October 11, 2012.
2. C.M. Balch, J.E. Gershenwald, S.J. Soong, J.F. Thompson, M.B. Atkins, and D.R. Byrd Final version of 2009 AJCC melanoma staging and classification J Clin Oncol 27 2009 6199 6206
3. C.M. Balch, J.E. Gershenwald, S.J. Soong, J.F. Thompson, S. Ding, and D.R. Byrd Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases J Clin Oncol 28 2010 2452 2459
4. A. Barth, L.A. Wanek, and D.L. Morton Prognostic factors in 1,521 melanoma patients with distant metastases J Am Coll Surg 181 1995 193 201
5. H. Tsao, G.S. Rogers, and A.J. Sober An estimate of the annual direct cost of treating cutaneous melanoma J Am Acad Dermatol 38 1998 669 680
6. A.M. Seidler, M.L. Pennie, E. Veledar, S.D. Culler, and S.C. Chen Economic burden of melanoma in the elderly population: population-based analysis of the Surveillance, Epidemiology, and End Results (SEER) - Medicare data Arch Dermatol 146 2010 249 256
7. C.K. Bichakjian, A.C. Halpern, T.M. Johnson, A. Foote Hood, J.M. Grichnik, and S.M. Swetter Guidelines of care for the management of primary cutaneous melanoma. American Academy of Dermatology J Am Acad Dermatol 65 2011 1032 1047
8. W.G. Stebbins, L. Garibyan, and A.J. Sober Sentinel lymph node biopsy and melanoma: 2010 update. Part I J Am Acad Dermatol 62 2010 723 734
9. W.G. Stebbins, L. Garibyan, and A.J. Sober Sentinel lymph node biopsy and melanoma: 2010 update. Part II J Am Acad Dermatol 62 2010 737 748
10. T.M. Johnson, V.K. Sondak, C.K. Bichakjian, and M.S. Sabel The role of sentinel lymph node biopsy for melanoma: evidence assessment J Am Acad Dermatol 54 2006 19 27
11. D.L. Morton, J.F. Thompson, A.J. Cochran, N. Mozzillo, R. Elashoff, and R. Essner Sentinel-node biopsy or nodal observation in melanoma N Engl J Med 355 2006 1307 1317
12. C. Gajdos, K.A. Griffith, S.L. Wong, T.M. Johnson, A.E. Chang, and V.M. Cimmino Is there a benefit to sentinel lymph node biopsy in patients with T4 melanoma? Cancer 115 2009 5752 5760
13. D.G. Coit, R. Andtbacka, C.J. Anker, C.K. Bichakjian, W.E. Carson 3rd, and A. Daud Melanoma J Natl Compr Canc Netw 10 2012 366 400
14. R.S. Bart, N.R. Porzio, A.W. Kopf, J.T. Vilcek, E.H. Cheng, and Y. Farcet Inhibition of growth of B16 murine malignant melanoma by exogenous interferon Cancer Res 40 1980 614 619
15. J.M. Kirkwood, M.H. Strawderman, M.S. Ernstoff, T.J. Smith, E.C. Borden, and R.H. Blum Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684 J Clin Oncol 14 1996 7 17
16. J.M. Kirkwood, J.G. Ibrahim, V.K. Sondak, J. Richards, L.E. Flaherty, and M.S. Ernstoff High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190 J Clin Oncol 18 2000 2444 2458
17. J.M. Kirkwood, J. Manola, J. Ibrahim, V. Sondak, M.S. Ernstoff, and U. Rao A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma Clin Cancer Res 10 2004 1670 1677
18. S. Mocellin, S. Pasquali, C.R. Rossi, and D. Nitti Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-Analysis J Natl Cancer Inst 102 2010 493 501
19. T. Petrella, S. Verma, K. Spithoff, I. Quirt, and D. McCready Adjuvant interferon therapy for patients at high risk for recurrent melanoma: an updated systematic review and practice guideline Clin Oncol (R Coll Radiol) 24 2012 413 423
20. H. Gogas, J. Ioannovich, U. Dafni, C. Stavropoulou-Giokas, K. Frangia, and D. Tsoutsos Prognostic significance of autoimmunity during treatment of melanoma with interferon N Engl J Med 354 2006 709 718
21. A.M. Eggermont, S. Suciu, M. Santinami, A. Testori, W.H. Kruit, and J. Marsden Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial Lancet 372 2008 117 126
22. A.M. Eggermont, S. Suciu, A. Testori, W.H. Kruit, J. Marsden, and C.J. Punt Ulceration and stage are predictive of interferon efficacy in melanoma: results of the phase III adjuvant trials EORTC 18952 and EORTC 18991 Eur J Cancer 48 2012 218 225
23. L. Flaherty, J. Moon, M.B. Atkins, R. Tuthill, J.A. Thompson, and J.T. Vetto Phase III trial of high-dose interferon alpha-2b versus cisplatin, vinblastine, DTIC plus IL-2 and interferon in patients with high-risk melanoma (SWOG S0008): an intergroup study of CALGB, COG, ECOG, and SWOG [abstract] J Clin Oncol 30 suppl 2012
24. B.A. Guadagnolo, and G.K. Zagars Adjuvant radiation therapy for high-risk nodal metastases from cutaneous melanoma Lancet Oncol 10 2009 409 416
25. W.M. Mendenhall, R.J. Amdur, S.R. Grobmyer, T.J. George Jr., J.W. Werning, and S.N. Hochwald Adjuvant radiotherapy for cutaneous melanoma Cancer 112 2008 1189 1196
26. S. Agrawal, J.M. Kane 3rd, B.A. Guadagnolo, W.G. Kraybill, and M.T. Ballo The benefits of adjuvant radiation therapy after therapeutic lymphadenectomy for clinically advanced, high-risk, lymph node-metastatic melanoma Cancer 115 2009 5836 5844
27. B.H. Burmeister, M.A. Henderson, J. Ainslie, R. Fisher, J. Di Iulio, and B.M. Smithers Adjuvant radiotherapy versus observation alone for patients at risk of lymph-node field relapse after therapeutic lymphadenectomy for melanoma: a randomised trial Lancet Oncol 13 2012 589 597
28. A. Calabro, S.E. Singletary, and C.M. Balch Patterns of relapse in 1001 consecutive patients with melanoma nodal metastases Arch Surg 124 1989 1051 1055
29. O. Creech Jr., E.T. Krementz, R.F. Ryan, and J.N. Winblad Chemotherapy of cancer: regional perfusion utilizing an extracorporeal circuit Ann Surg 148 1958 616 632
30. O. Creech Jr., E.T. Krementz, R.F. Ryan, K. Reemtsma, and J.N. Winblad Experiences with isolation-perfusion technics in the treatment of cancer Ann Surg 149 1959 627 640
31. J.F. Thompson, P.C. Kam, R.C. Waugh, and C.R. Harman Isolated limb infusion with cytotoxic agents: a simple alternative to isolated limb perfusion Semin Surg Oncol 14 1998 238 247
32. A. Testori, C. Verhoef, H.M. Kroon, E. Pennacchioli, M.B. Faries, and A.M. Eggermont Treatment of melanoma metastases in a limb by isolated limb perfusion and isolated limb infusion J Surg Oncol 104 2011 397 404
33. M.B. Lens, and M. Dawes Isolated limb perfusion with melphalan in the treatment of malignant melanoma of the extremities: a systematic review of randomised controlled trials Lancet Oncol 4 2003 359 364
34. H.S. Koops, M. Vaglini, S. Suciu, B.B. Kroon, J.F. Thompson, and J. Gohl Prophylactic isolated limb perfusion for localized, high-risk limb melanoma: results of a multicenter randomized phase III trial. European Organization for Research and Treatment of Cancer Malignant Melanoma Cooperative Group Protocol 18832, the World Health Organization Melanoma Program Trial 15, and the North American Perfusion Group Southwest Oncology Group-8593 J Clin Oncol 16 1998 2906 2912
35. D. Moreno-Ramirez, L. de la Cruz-Merino, L. Ferrandiz, R. Villegas-Portero, and A. Nieto-Garcia Isolated limb perfusion for malignant melanoma: systematic review on effectiveness and safety Oncologist 15 2010 416 427
36. C.E. Boesch, T. Meyer, L. Waschke, S. Merkel, J. Goehl, and W. Hohenberger Long-term outcome of hyperthermic isolated limb perfusion (HILP) in the treatment of locoregionally metastasised malignant melanoma of the extremities Int J Hyperthermia 26 2010 16 20
37. G.M. Beasley, A. Caudle, R.P. Petersen, N.S. McMahon, J. Padussis, and P.J. Mosca A multi-institutional experience of isolated limb infusion: defining response and toxicity in the US J Am Coll Surg 208 2009 706 715
38. J.K. Tan, and V.C. Ho Pooled analysis of the efficacy of bacille Calmette-Guerin (BCG) immunotherapy in malignant melanoma J Dermatol Surg Oncol 19 1993 985 990
39. I.H. Wolf, E. Richtig, D. Kopera, and H. Kerl Locoregional cutaneous metastases of malignant melanoma and their management Dermatol Surg 30 2004 244 247
40. M.L. Nasi, P. Lieberman, K.J. Busam, V. Prieto, K.S. Panageas, and J.J. Lewis Intradermal injection of granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with metastatic melanoma recruits dendritic cells Cytokines Cell Mol Ther 5 1999 139 144
41. C. Hoeller, B. Jansen, E. Heere-Ress, T. Pustelnik, U. Mossbacher, and H. Schlagbauer-Wadl Perilesional injection of r-GM-CSF in patients with cutaneous melanoma metastases J Invest Dermatol 117 2001 371 374
42. D.S. Green, M.D. Bodman-Smith, A.G. Dalgleish, and M.D. Fischer Phase I/II study of topical imiquimod and intralesional interleukin-2 in the treatment of accessible metastases in malignant melanoma Br J Dermatol 156 2007 337 345
43. J. Utikal, A. Zimpfer, A. Thoelke, R. Figl, R. Hildenbrand, and C. Kettelhack Complete remission of multiple satellite and in-transit melanoma metastases after sequential treatment with isolated limb perfusion and topical imiquimod Br J Dermatol 155 2006 488 491
44. G. Heber, D. Helbig, I. Ponitzsch, T. Wetzig, W. Harth, and J.C. Simon Complete remission of cutaneous and subcutaneous melanoma metastases of the scalp with imiquimod therapy J Dtsch Dermatol Ges 7 2009 534 536
45. K. Turza, L.T. Dengel, R.C. Harris, J.W. Patterson, K. White, and W.W. Grosh Effectiveness of imiquimod limited to dermal melanoma metastases, with simultaneous resistance of subcutaneous metastasis J Cutan Pathol 37 2010 94 98
46. M. Sigüenza, A. Pizarro, M. Mayor, C. Vidaurrázaga, L. Miralles, and M. González-Beato Topical treatment of melanoma skin metastases with imiquimod [in Spanish] Actas Dermosifiliogr 96 2005 111 115
47. V. Florin, E. Desmedt, S. Vercambre-Darras, and L. Mortier Topical treatment of cutaneous metastases of malignant melanoma using combined imiquimod and 5-fluorouracil Invest New Drugs 30 2012 1641 1645
48. J.F. Thompson, P. Hersey, and E. Wachter Chemoablation of metastatic melanoma using intralesional rose bengal Melanoma Res 18 2008 405 411